JPWO2021097325A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021097325A5 JPWO2021097325A5 JP2022528263A JP2022528263A JPWO2021097325A5 JP WO2021097325 A5 JPWO2021097325 A5 JP WO2021097325A5 JP 2022528263 A JP2022528263 A JP 2022528263A JP 2022528263 A JP2022528263 A JP 2022528263A JP WO2021097325 A5 JPWO2021097325 A5 JP WO2021097325A5
- Authority
- JP
- Japan
- Prior art keywords
- subfamily
- tcrβ
- subject
- cancer
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024198993A JP2025024094A (ja) | 2019-11-14 | 2024-11-14 | 抗ｔｃｒ抗体分子およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962935172P | 2019-11-14 | 2019-11-14 | |
| US62/935,172 | 2019-11-14 | ||
| US202062956969P | 2020-01-03 | 2020-01-03 | |
| US62/956,969 | 2020-01-03 | ||
| PCT/US2020/060557 WO2021097325A1 (en) | 2019-11-14 | 2020-11-13 | Anti-tcr antibody molecules and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024198993A Division JP2025024094A (ja) | 2019-11-14 | 2024-11-14 | 抗ｔｃｒ抗体分子およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023501722A JP2023501722A (ja) | 2023-01-18 |
| JP2023501722A5 JP2023501722A5 (https=) | 2024-05-13 |
| JPWO2021097325A5 true JPWO2021097325A5 (https=) | 2024-05-13 |
| JP7590430B2 JP7590430B2 (ja) | 2024-11-26 |
Family
ID=75912403
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022528263A Active JP7590430B2 (ja) | 2019-11-14 | 2020-11-13 | 抗ｔｃｒ抗体分子およびその使用 |
| JP2024198993A Pending JP2025024094A (ja) | 2019-11-14 | 2024-11-14 | 抗ｔｃｒ抗体分子およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024198993A Pending JP2025024094A (ja) | 2019-11-14 | 2024-11-14 | 抗ｔｃｒ抗体分子およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230048244A1 (https=) |
| EP (1) | EP4058483A4 (https=) |
| JP (2) | JP7590430B2 (https=) |
| CN (1) | CN115003698A (https=) |
| AU (2) | AU2020384369B2 (https=) |
| CA (1) | CA3160997A1 (https=) |
| GB (1) | GB2607452B (https=) |
| WO (1) | WO2021097325A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス，インコーポレーテッド | Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| WO2023056556A1 (en) * | 2021-10-07 | 2023-04-13 | National Research Council Of Canada | Anti-cd3 monoclonal antibodies and therapeutic constructs |
| WO2023081412A2 (en) * | 2021-11-05 | 2023-05-11 | Marengo Therapeutics, Inc. | Immune cell populations and uses thereof |
| EP4601747A1 (en) * | 2022-10-12 | 2025-08-20 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
| AU2024240821A1 (en) | 2023-03-23 | 2025-11-06 | Bodhi Bio Llc | Compositions and methods for antigen-specific therapy |
| WO2025051339A1 (en) * | 2023-09-05 | 2025-03-13 | Tiber Biotech Srl | SINGLE-CHAIN VARIABLE FRAGMENT AND MOLECULES DERIVING THEREFROM THAT BIND FRAGMENT TRVB5-1 OF THE β CHAIN OF HUMAN T-CELL RECEPTOR |
| WO2025245071A1 (en) * | 2024-05-21 | 2025-11-27 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5766947A (en) * | 1988-12-14 | 1998-06-16 | Astra Ab | Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor |
| US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
| AU5245399A (en) * | 1998-07-29 | 2000-02-21 | Heska Corporation | T cell receptor proteins, nucleic acid molecules, and uses thereof |
| DK2336187T3 (en) * | 2000-06-19 | 2016-08-22 | Beth Israel Deaconess Medical Ct Inc | Compositions and Methods of monoclonal and polyclonal antibodies which are specific for T-cell subpopulations |
| GB0328363D0 (en) * | 2003-12-06 | 2004-01-14 | Imp College Innovations Ltd | Therapeutically useful molecules |
| US9018006B2 (en) * | 2010-07-23 | 2015-04-28 | The University Of Toledo | Stable Tregs and related materials and methods |
| ES2534782T3 (es) * | 2012-02-02 | 2015-04-28 | Baylor College Of Medicine | Sistema biológico de administración y expresión basado en adenovirus para uso en el tratamiento de la osteoartritis |
| SG11201603193PA (en) * | 2013-10-30 | 2016-05-30 | Genzyme Corp | Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide |
| WO2016193301A1 (en) * | 2015-06-01 | 2016-12-08 | Medigene Immunotherapies Gmbh | T-cell receptor specific antibodies |
| EP3818083A2 (en) * | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| GB2595980B (en) * | 2019-01-04 | 2023-06-14 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| AU2020226904B2 (en) * | 2019-02-21 | 2025-05-01 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| CN116234829A (zh) * | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| WO2023081412A2 (en) * | 2021-11-05 | 2023-05-11 | Marengo Therapeutics, Inc. | Immune cell populations and uses thereof |
-
2020
- 2020-11-13 JP JP2022528263A patent/JP7590430B2/ja active Active
- 2020-11-13 WO PCT/US2020/060557 patent/WO2021097325A1/en not_active Ceased
- 2020-11-13 AU AU2020384369A patent/AU2020384369B2/en active Active
- 2020-11-13 EP EP20886222.7A patent/EP4058483A4/en active Pending
- 2020-11-13 CA CA3160997A patent/CA3160997A1/en active Pending
- 2020-11-13 CN CN202080093361.9A patent/CN115003698A/zh active Pending
- 2020-11-13 GB GB2208378.6A patent/GB2607452B/en active Active
-
2022
- 2022-05-16 US US17/745,456 patent/US20230048244A1/en active Pending
-
2024
- 2024-11-14 JP JP2024198993A patent/JP2025024094A/ja active Pending
-
2025
- 2025-05-12 AU AU2025203410A patent/AU2025203410A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2607452A (en) | Anti-TCR antibody molecules and uses thereof | |
| AU2004283850B2 (en) | Multispecific deimmunized CD3-binders | |
| US7919089B2 (en) | Pharmaceutical composition comprising a bispecific antibody for EpCAM | |
| CA2523716C (en) | Human anti-human cd3 binding molecules | |
| JP2022169543A (ja) | 改善された養子ｔ細胞療法 | |
| JP6574381B2 (ja) | 細胞免疫療法のための方法および組成物 | |
| US20210137977A1 (en) | Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy | |
| Shi et al. | Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects | |
| IL271325B1 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| CA2903096A1 (en) | Oncolytic virus | |
| JPWO2021097325A5 (https=) | ||
| US20180028631A1 (en) | Anti-ssea4 chimeric antigen receptors and their use for treating cancer | |
| JP2023548974A (ja) | Ｔ細胞抗原カプラを含む細胞及びその使用 | |
| EP4232566A1 (en) | Chimeric activation receptors | |
| Hayashi et al. | A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells | |
| CN114437214B (zh) | 靶向lir1的抗体及其用途 | |
| CN114853897B (zh) | 抗cd19/cd22/cd3三特异性抗体及用途 | |
| US20180028632A1 (en) | Method of treating tumors with nk and nkt cells expressing anti-ssea4 chimeric antigen receptors | |
| JPWO2020092467A5 (https=) | ||
| ZA200508279B (en) | Pharmaceutical composition comprising a bispecific antibody for epcam | |
| JPWO2022098914A5 (https=) | ||
| HK40084777A (en) | Anti-tcr antibody molecules and uses thereof | |
| Wei et al. | Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity | |
| JPWO2022099297A5 (https=) | ||
| Epperly et al. | Biology and Clinical Evaluation of T/NK Cell Engagers |